**TL;DR:** BSX is a well-run medtech company with strong tailwinds, but at $92 it's priced for perfection. Fair value sits around $62-78. Worth watching, not buying.
---
## The Story
Mike Mahoney took over a struggling $7B company in 2012, buried in debt from the Guidant disaster. Fourteen years later, he's built it into a $16.7B global leader. That's a 403% return vs ~110% for the S&P.
The crown jewels:
- **FARAPULSE** - their pulsed field ablation system hit $1B revenue in year one. 500,000 patients treated. It's eating the AFib market.
- **WATCHMAN** - $512M in Q3 alone (+35% YoY). Left atrial appendage closure with no real competition.
Now they're going after Penumbra for $14.5B—re-entering the neurovascular game they sold to Stryker back in 2011.
---
## The Numbers That Matter
**Growth is real:**
- Revenue: $12.7B (2022) → $16.7B (2024) → $20B+ (2025E)
- Free Cash Flow: Tripled from $950M to $2.65B in two years
- Operating margins expanding ~300+ bps YoY
**But the valuation is stretched:**
| Metric | Current |
|--------|---------|
| P/E | 30-37x |
| FCF Yield | ~2% |
| Price vs Fair Value | 18-48% premium |
At $92, you're not getting a margin of safety—you're paying a premium.
---
## The Bull Case
- Aging population = more heart procedures. Adults 65+ hitting 22% of global pop by 2030.
- FARAPULSE dominance should hold—60%+ of AFib procedures expected to use PFA by 2026
- Management has a solid M&A playbook (40+ deals under Mahoney)
- Operating leverage kicking in as high-margin products scale
---
## The Concerns
- **Valuation risk:** Everything has to go right. Any stumble and you're looking at 30%+ downside just from multiple compression.
- **Penumbra integration:** $14.5B is their biggest deal in 20 years. Near-term dilutive, adds ~$11B in debt.
- **Competition heating up:** Medtronic and Abbott are ramping their PFA offerings. Citi surveys show Medtronic gaining physician mindshare.
---
## What Would Get Me Interested
If the market gave us a 35-40% correction, putting BSX in the $55-60 range, the math starts working:
| Entry | Return Profile |
|-------|---------------|
| $92 | ~8% annual (base case) |
| $60 | ~12-14% annual |
Right now you're paying for 10 years of execution upfront.
---
## Bottom Line
This is a well-managed company with real competitive advantages in a growing market. The CEO's track record is legit. The products are winning.
But as value investors, we care about price. At $92, the stock needs everything to go right just to deliver average market returns. A couple of missed quarters or some Penumbra integration hiccups, and you're underwater for years.
**Verdict:** Great business, wrong price. Watch list, not buy list.